Controversies in papillary microcarcinoma of the thyroid

被引:51
作者
Piersanti, M
Ezzat, S
Asa, SL
机构
[1] Mt Sinai Hosp, Dept Med, New York, NY 10029 USA
[2] Univ Toronto, Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Freeman Ctr Endocrine Oncol, Toronto, ON M5G 2M9, Canada
[4] Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
关键词
thyroid; microcarcinoma; papillary carcinoma; ret/PTC;
D O I
10.1385/EP:14:3:183
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Papillary thyroid carcinomas that are smaller than 1 cm are classified as papillary microcarcinomas (PMC). These lesions are frequently detected as incidental findings on autopsy or in surgical specimens. They are often multifocal. The relationship between PMC and clinical papillary thyroid carcinoma (PTC) is not clear. In patients with clinical thyroid cancer, PMC may represent intrathyroidal metastases; they may be the earliest form of future large lesions. These uncertainties raise questions about appropriate clinical management of patients with these lesions. Review of the literature substantiates the argument that clinically evident PTC may be distinctly different from solitary or multifocal PMC in terms of etiology and biologic behavior, supporting a conservative approach to management.
引用
收藏
页码:183 / 191
页数:9
相关论文
共 81 条
  • [1] INCIDENCE PATTERN OF THYROID-CANCER IN NORWAY - INFLUENCE OF BIRTH COHORT AND TIME PERIOD
    AKSLEN, LA
    HALDORSEN, T
    THORESEN, SO
    GLATTRE, E
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 53 (02) : 183 - 187
  • [2] BISI H, 1989, CANCER, V64, P1888, DOI 10.1002/1097-0142(19891101)64:9<1888::AID-CNCR2820640922>3.0.CO
  • [3] 2-C
  • [4] BLACK B M, 1948, West J Surg Obstet Gynecol, V56, P134
  • [5] BONDESON L, 1984, CANCER-AM CANCER SOC, V53, P1790, DOI 10.1002/1097-0142(19840415)53:8<1790::AID-CNCR2820530831>3.0.CO
  • [6] 2-9
  • [7] Different significance of ret/PTC1 and ret/PTC3 rearrangements in thyroid carcinogenesis:: Lesson from two subgroups of patients with papillary thyroid carcinomas showing the highest incidence of ret/PTC activation
    Cetta, F
    Gori, M
    Montalto, G
    Zuckermann, M
    Toti, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) : 1429 - 1429
  • [8] NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA
    DEGROOT, LJ
    KAPLAN, EL
    MCCORMICK, M
    STRAUS, FH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) : 414 - 424
  • [9] Fink A, 1996, MODERN PATHOL, V9, P816
  • [10] FRANSSILA KO, 1986, CANCER, V58, P715, DOI 10.1002/1097-0142(19860801)58:3<715::AID-CNCR2820580319>3.0.CO